Non-small cell lung cancer stage III
Information
- Disease name
- Non-small cell lung cancer stage III
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04685070 | Active, not recruiting | Phase 2 | Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer | December 14, 2021 | December 31, 2027 |
| NCT04765709 | Active, not recruiting | Phase 2 | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | September 24, 2021 | June 2026 |
| NCT04699721 | Active, not recruiting | Phase 1 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC | July 1, 2020 | December 2027 |
| NCT02623257 | Completed | EGFR Mutations on ctDNA in Patients With Advanced NSCLC | January 2016 | December 2017 | |
| NCT03550482 | Completed | Phase 4 | Oncoxin® and Quality of Life in Cancer Patients | November 1, 2017 | May 15, 2019 |
| NCT03728556 | Completed | Phase 3 | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | October 26, 2018 | April 3, 2023 |
| NCT02418234 | Completed | T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure | March 2015 | November 2017 | |
| NCT02434081 | Completed | Phase 2 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma | November 25, 2015 | March 31, 2020 |
| NCT03743129 | Completed | Phase 2 | Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） | April 12, 2019 | November 11, 2021 |
| NCT02053285 | Completed | Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer | January 2014 | February 20, 2020 | |
| NCT06015815 | Completed | The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT | October 5, 2019 | August 15, 2020 | |
| NCT06031597 | Not yet recruiting | Phase 3 | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | September 15, 2023 | December 31, 2025 |
| NCT06449313 | Not yet recruiting | Phase 2 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer | September 2024 | September 2032 |
| NCT05451173 | Not yet recruiting | Phase 1/Phase 2 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | October 9, 2023 | December 31, 2025 |
| NCT05414630 | Not yet recruiting | Phase 2 | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | June 2022 | June 2025 |
| NCT06463665 | Not yet recruiting | Phase 2 | Efficacy & Safety of Olvimulogene Nanivacirepvec and Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared With Docetaxel in NSCL Cancer (VIRO-25) | July 2024 | July 2029 |
| NCT05548504 | Not yet recruiting | Phase 2 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | October 1, 2022 | September 30, 2029 |
| NCT04728724 | Recruiting | Phase 2 | Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer | September 10, 2022 | December 31, 2027 |
| NCT04585477 | Recruiting | Phase 2 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | April 8, 2021 | April 2026 |
| NCT04716946 | Recruiting | Phase 2 | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | January 27, 2021 | February 2025 |
| NCT04878952 | Recruiting | N/A | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer | January 5, 2024 | July 10, 2026 |
| NCT05031533 | Recruiting | N/A | Dose-painting Radiation for LA-NSCLC | January 1, 2021 | December 2025 |
| NCT05338619 | Recruiting | Phase 2 | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy | June 30, 2022 | March 2, 2026 |
| NCT05398094 | Recruiting | Phase 2 | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | March 21, 2022 | December 31, 2028 |
| NCT05557552 | Recruiting | N/A | Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer | September 30, 2022 | September 30, 2026 |
| NCT02412371 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | April 30, 2015 | August 5, 2019 |
| NCT04749407 | Unknown status | Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer | February 2021 | December 2022 | |
| NCT01683175 | Unknown status | Phase 2 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | August 2012 | October 2020 |
| NCT04586465 | Unknown status | Phase 2 | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC | October 10, 2020 | June 30, 2022 |
| NCT02946216 | Unknown status | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC | November 2016 | November 2018 | |
| NCT04941365 | Withdrawn | N/A | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy | July 7, 2022 | March 2024 |